Navigation Menu Toggle navigation Sign in Product ...

Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency for two of its drugs. The ...

Opdivo (nivolumab) isn’t known to interact with supplements or other medications. Opdivo is used in adults to treat certain types of cancer. These include: An interaction can occur because one ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...

Opdivo Qvantig (nivolumab and hyaluronidase ... drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab ...

Opdivo contains the medicine nivolumab. It acts on proteins on the ... Opdivo Qvantig is a subcutaneous (under-the-skin) injection in your stomach area or thigh. It is given by a healthcare ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.